Total Payments
$28,293
2024 Payments
$2,550
Companies
13
Transactions
32
Medicare Patients
924
Medicare Billing
$231,289
Payment Breakdown by Category
Consulting$17,492 (61.8%)
Other$7,438 (26.3%)
Research$1,601 (5.7%)
Travel$1,281 (4.5%)
Food & Beverage$457.54 (1.6%)
Education$23.35 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $17,492 | 7 | 61.8% |
| Honoraria | $4,438 | 2 | 15.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,000 | 1 | 10.6% |
| Unspecified | $1,601 | 3 | 5.7% |
| Travel and Lodging | $1,281 | 5 | 4.5% |
| Food and Beverage | $457.54 | 12 | 1.6% |
| Education | $23.35 | 2 | 0.1% |
Payments by Type
General
$26,692
29 transactions
Research
$1,601
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $4,284 | 5 | $0 (2023) |
| Seattle Genetics, Inc. | $3,729 | 9 | $0 (2017) |
| Kite Pharma, Inc. | $3,645 | 3 | $0 (2019) |
| Karyopharm Therapeutics Inc. | $3,500 | 3 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $3,222 | 1 | $0 (2017) |
| MorphoSys, US Inc. | $2,768 | 1 | $0 (2022) |
| Gamida Cell Inc. | $2,550 | 1 | $0 (2024) |
| Incyte Corporation | $2,153 | 1 | $0 (2021) |
| Pharmacyclics LLC, An AbbVie Company | $1,798 | 3 | $0 (2018) |
| SANOFI-AVENTIS U.S. LLC | $330.92 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,550 | 1 | Gamida Cell Inc. ($2,550) |
| 2023 | $1,462 | 4 | PFIZER INC. ($1,273) |
| 2022 | $5,768 | 2 | PFIZER INC. ($3,000) |
| 2021 | $3,703 | 2 | Incyte Corporation ($2,153) |
| 2020 | $1,950 | 2 | Karyopharm Therapeutics Inc. ($1,950) |
| 2019 | $3,645 | 3 | Kite Pharma, Inc. ($3,645) |
| 2018 | $1,918 | 6 | Pharmacyclics LLC, An AbbVie Company ($1,798) |
| 2017 | $7,297 | 12 | Seattle Genetics, Inc. ($3,729) |
All Payment Transactions
32 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/19/2024 | Gamida Cell Inc. | OMISIRGE (Biological) | Consulting Fee | Cash or cash equivalent | $2,550.00 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2023 | PFIZER INC. | ELREXFIO (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: ELRANATAMAB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 09/22/2023 | PFIZER INC. | BOSULIF (Drug), BESPONSA, ELREXFIO | Food and Beverage | In-kind items and services | $2.71 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 08/01/2023 | PFIZER INC. | ELREXFIO (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: ELRANATAMAB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 07/05/2023 | National Marrow Donor Program | — | Travel and Lodging | In-kind items and services | $189.04 | General |
| 06/21/2022 | MorphoSys, US Inc. | MONJUVI (Drug) | Consulting Fee | Cash or cash equivalent | $2,767.50 | General |
| Category: Oncology | ||||||
| 03/10/2022 | PFIZER INC. | BESPONSA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| Category: ONCOLOGY | ||||||
| 10/13/2021 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $2,152.50 | General |
| 03/31/2021 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Consulting Fee | Cash or cash equivalent | $1,550.00 | General |
| Category: Oncology | ||||||
| 11/16/2020 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Education | In-kind items and services | $12.45 | General |
| Category: Oncology | ||||||
| 08/12/2020 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Honoraria | Cash or cash equivalent | $1,937.50 | General |
| Category: Oncology | ||||||
| 06/19/2019 | Kite Pharma, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,500.00 | General |
| 05/30/2019 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $97.49 | General |
| 05/30/2019 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $47.75 | General |
| 07/17/2018 | PFIZER INC. | BESPONSA (Biological) | Education | In-kind items and services | $10.90 | General |
| Category: ONCOLOGY | ||||||
| 05/03/2018 | Novartis Pharmaceuticals Corporation | KYMRIAH (Biological) | Food and Beverage | In-kind items and services | $11.06 | General |
| Category: ONCOLOGY | ||||||
| 03/13/2018 | Pharmacyclics LLC, An AbbVie Company | Imbruvica (Drug) | Consulting Fee | Cash or cash equivalent | $1,750.00 | General |
| Category: Oncology | ||||||
| 02/24/2018 | Pharmacyclics LLC, An AbbVie Company | Imbruvica (Drug) | Food and Beverage | In-kind items and services | $41.11 | General |
| Category: Oncology | ||||||
| 02/24/2018 | Pharmacyclics LLC, An AbbVie Company | Imbruvica (Drug) | Food and Beverage | In-kind items and services | $6.97 | General |
| Category: Oncology | ||||||
| 02/23/2018 | Jazz Pharmaceuticals Inc. | Defitelio (Drug) | Food and Beverage | In-kind items and services | $98.14 | General |
| Category: Hematology | ||||||
| 09/04/2017 | Seattle Genetics, Inc. | SGN35 (Biological) | Honoraria | Cash or cash equivalent | $2,500.00 | General |
| Category: Not Applicable | ||||||
| 09/04/2017 | Seattle Genetics, Inc. | SGN35 (Biological) | Travel and Lodging | In-kind items and services | $598.40 | General |
| Category: Not Applicable | ||||||
| 09/04/2017 | Seattle Genetics, Inc. | SGN35 (Biological) | Travel and Lodging | In-kind items and services | $289.84 | General |
| Category: Not Applicable | ||||||
| 09/04/2017 | Seattle Genetics, Inc. | SGN35 (Biological) | Travel and Lodging | In-kind items and services | $111.35 | General |
| Category: Not Applicable | ||||||
| 09/04/2017 | Seattle Genetics, Inc. | SGN35 (Biological) | Travel and Lodging | In-kind items and services | $92.67 | General |
| Category: Not Applicable | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ELRANATAMAB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,270 | 2 |
| Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin?s Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report | SANOFI-AVENTIS U.S. LLC | $330.92 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 95 | 333 | $106,154 | $32,877 |
| 2022 | 5 | 119 | 242 | $75,366 | $16,462 |
| 2021 | 4 | 291 | 753 | $345,038 | $67,342 |
| 2020 | 7 | 419 | 1,423 | $358,651 | $114,608 |
Total Patients
924
Total Services
2,751
Medicare Billing
$231,289
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 31 | 233 | $62,402 | $22,933 | 36.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 22 | 30 | $18,055 | $4,139 | 22.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 19 | 42 | $17,577 | $3,270 | 18.6% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 23 | 28 | $8,120 | $2,534 | 31.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 17 | 124 | $32,364 | $10,564 | 32.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 65 | 76 | $31,616 | $2,976 | 9.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 15 | 16 | $9,280 | $2,646 | 28.5% |
| 84165 | Protein measurement, serum | Facility | 2022 | 11 | 13 | $1,053 | $138.36 | 13.1% |
| 86334 | Immunologic analysis technique on serum (immunofixation) | Facility | 2022 | 11 | 13 | $1,053 | $138.36 | 13.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 179 | 496 | $202,216 | $36,895 | 18.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 45 | 154 | $93,159 | $19,176 | 20.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 26 | 60 | $24,960 | $5,929 | 23.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 15 | 15 | $11,061 | $2,415 | 21.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 11 | 11 | $8,338 | $1,856 | 22.3% |
| 38222 | Diagnostic aspirations and biopsies of bone marrow | Facility | 2021 | 15 | 17 | $5,304 | $1,072 | 20.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 191 | 586 | $119,847 | $35,225 | 29.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 39 | 354 | $92,394 | $31,507 | 34.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 67 | 308 | $88,704 | $28,898 | 32.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 28 | 72 | $14,712 | $5,837 | 39.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 19 | 24 | $13,920 | $4,173 | 30.0% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 22 | 22 | $9,878 | $3,460 | 35.0% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 20 | 23 | $6,670 | $2,096 | 31.4% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 14 | 14 | $6,286 | $2,051 | 32.6% |
| 38222 | Bone marrow biopsy and aspiration | Facility | 2020 | 19 | 20 | $6,240 | $1,361 | 21.8% |
About Dr. Patrick Stiff, MD
Dr. Patrick Stiff, MD is a Hematology & Oncology healthcare provider based in Maywood, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/30/2005. The National Provider Identifier (NPI) number assigned to this provider is 1558348433.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Patrick Stiff, MD has received a total of $28,293 in payments from pharmaceutical and medical device companies, with $2,550 received in 2024. These payments were reported across 32 transactions from 13 companies. The most common payment nature is "Consulting Fee" ($17,492).
As a Medicare-enrolled provider, Stiff has provided services to 924 Medicare beneficiaries, totaling 2,751 services with total Medicare billing of $231,289. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Maywood, IL
- Active Since 12/30/2005
- Last Updated 11/15/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1558348433
Products in Payments
- SGN35 (Biological) $3,729
- XPOVIO (Drug) $3,500
- BESPONSA (Biological) $3,011
- MONJUVI (Drug) $2,768
- OMISIRGE (Biological) $2,550
- Imbruvica (Drug) $1,798
- ELREXFIO (Drug) $1,270
- MOZOBIL (Drug) $330.92
- Defitelio (Drug) $98.14
- KYMRIAH (Biological) $11.06
- BOSULIF (Drug) $2.71
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Maywood
Mohamad Khair Khasawneh, Md, MD
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Stephanie Tsai, M.d, M.D
Hematology & Oncology — Payments: $141,544
Hematology & Oncology $141,544
Agne Paner, M.d, M.D
Hematology & Oncology — Payments: $131,263
Hematology & Oncology $131,263
Patrick Hagen, M.d., M.p.h, M.D., M.P.H
Hematology & Oncology — Payments: $118,454
Hematology & Oncology $118,454
Joseph Clark, Md, MD
Hematology & Oncology — Payments: $102,053
Hematology & Oncology $102,053
Scott Smith, Md Phd, MD PHD
Hematology & Oncology — Payments: $101,319
Hematology & Oncology $101,319